These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 29141124

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):69-76. PubMed ID: 28839342
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS, Calabrese JR, Nierenberg AA, Farahmand K, Yonan C, Siegert S, Burke J.
    J Affect Disord; 2019 Mar 01; 246():217-223. PubMed ID: 30583148
    [Abstract] [Full Text] [Related]

  • 7. The effects of valbenazine on tardive dyskinesia in older and younger patients.
    Sajatovic M, Alexopoulos GS, Burke J, Farahmand K, Siegert S.
    Int J Geriatr Psychiatry; 2020 Jan 01; 35(1):69-79. PubMed ID: 31617235
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A long-term, open-label study of valbenazine for tardive dyskinesia.
    Lindenmayer JP, Verghese C, Marder SR, Burke J, Jimenez R, Siegert S, Liang GS, O'Brien CF.
    CNS Spectr; 2021 Aug 01; 26(4):345-353. PubMed ID: 32419679
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F, Luther K, Talreja O.
    Am J Health Syst Pharm; 2020 Jan 24; 77(3):167-174. PubMed ID: 31974564
    [Abstract] [Full Text] [Related]

  • 16. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K.
    Tremor Other Hyperkinet Mov (N Y); 2024 Jan 24; 14():13. PubMed ID: 38497033
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N.
    Drugs Today (Barc); 2016 Dec 24; 52(12):665-672. PubMed ID: 28276538
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2017 Jul 24; 71(7):. PubMed ID: 28497864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.